E72.12 Methylenetetrahydrofolate reductase deficiency

Name of the Condition

• Methylenetetrahydrofolate reductase deficiency (ICD-10 Code: E72.12)

Summary

Methylenetetrahydrofolate reductase (MTHFR) deficiency is a rare genetic disorder affecting folate metabolism. This condition impairs the body’s ability to process folate, a B-vitamin essential for DNA synthesis and methylation processes. The deficiency can lead to elevated levels of homocysteine and reduced levels of methylated folate derivatives, potentially causing neurological, hematological, or vascular complications. Clinical presentation varies, with some individuals remaining asymptomatic while others experience developmental delays or other systemic effects.

Causes

MTHFR deficiency is caused by genetic mutations in the MTHFR gene, which encodes the enzyme methylenetetrahydrofolate reductase. These mutations reduce the enzyme’s activity, disrupting the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a key step in folate metabolism. Most cases follow an autosomal recessive inheritance pattern, requiring two mutated gene copies for the condition to manifest. The specific mutation type influences the severity of enzyme dysfunction and clinical outcomes.

Risk Factors

• Family history of MTHFR deficiency or related metabolic disorders.
• Consanguinity (parents who are close relatives), increasing the likelihood of inheriting recessive mutations.
• Ethnic or geographic prevalence of specific MTHFR gene variants in certain populations.

Symptoms

• Neurological symptoms such as developmental delays, intellectual disability, or seizures.
• Hematological issues like megaloblastic anemia or thrombosis.
• Vascular complications, including elevated homocysteine levels associated with increased cardiovascular risk.
• Fatigue, headaches, or mood disturbances in some cases.

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, laboratory testing, and genetic analysis. Blood tests may measure homocysteine and folate levels, which are often abnormal in MTHFR deficiency. Enzyme activity assays can assess MTHFR function, while genetic testing confirms the presence of pathogenic mutations in the MTHFR gene. Prenatal testing may be considered for families with a known history of the disorder.

Treatment Options

Treatment focuses on managing symptoms and addressing metabolic imbalances. Folate supplementation, often with L-methylfolate (the active form), is commonly used to normalize folate levels and reduce homocysteine. In severe cases, additional therapies may target specific complications, such as anticoagulants for thrombosis or antiepileptics for seizures. Dietary modifications, including increased intake of folate-rich foods, may support overall management.

Prognosis and Follow-Up

Prognosis varies depending on the severity of the mutation and the presence of complications. Early diagnosis and treatment can improve outcomes, particularly in preventing neurological or vascular issues. Regular follow-up is recommended to monitor homocysteine and folate levels, adjust supplementation as needed, and address any emerging symptoms. Lifelong management is often necessary to maintain metabolic balance.

Complications

• Neurological complications, including developmental delays or seizures.
• Vascular events, such as stroke or thrombosis, due to elevated homocysteine.
• Hematological issues like anemia or clotting disorders.
• Increased risk of pregnancy complications, such as neural tube defects, in affected individuals.

Lifestyle & Prevention

• Adherence to prescribed folate supplementation to maintain metabolic balance.
• Regular monitoring of homocysteine and folate levels as directed by a healthcare provider.
• Avoidance of factors that may exacerbate symptoms, such as smoking or excessive alcohol consumption.
• Genetic counseling for families with a history of MTHFR deficiency to discuss reproductive risks.

When to Seek Professional Help

Seek medical attention if experiencing unexplained neurological symptoms (e.g., seizures, developmental delays), signs of anemia (e.g., fatigue, shortness of breath), or vascular events (e.g., chest pain, sudden weakness). Prompt evaluation is important for early diagnosis and intervention, especially in individuals with a family history of metabolic disorders.

Tips for Medical Coders

When coding for MTHFR deficiency (E72.12), ensure documentation supports the diagnosis, including clinical findings, laboratory results, and genetic confirmation. Note that this code is specific to the enzyme deficiency and should not be used for other folate-related disorders. Verify that the code aligns with the patient’s documented condition and that any associated complications are coded separately if applicable.